PubRank

Peter Schraml

Author PubWeight™ 57.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004 2.55
2 Prevalence of KIT expression in human tumors. J Clin Oncol 2004 2.40
3 Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol 2009 2.06
4 Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun 2012 2.06
5 VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 2009 1.65
6 Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 2007 1.62
7 Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004 1.53
8 A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 2011 1.48
9 E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004 1.40
10 Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012 1.37
11 Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013 1.35
12 Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 2005 1.30
13 Different types of microsatellite instability in ovarian carcinoma. Int J Cancer 2004 1.30
14 Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2012 1.27
15 Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer 2010 1.21
16 HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 2004 1.15
17 Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002 1.14
18 Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006 1.07
19 Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2009 1.06
20 Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 2004 1.06
21 VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res 2011 1.05
22 Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 2013 1.05
23 αv-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 2013 1.01
24 IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 2010 1.01
25 Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007 1.01
26 TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 2004 1.00
27 L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis 2010 0.98
28 Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 2013 0.97
29 KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. J Mol Diagn 2013 0.95
30 Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Res 2011 0.95
31 Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol 2015 0.94
32 Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer 2011 0.94
33 Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol 2012 0.93
34 Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012 0.92
35 Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer 2006 0.91
36 Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia 2013 0.91
37 Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 2009 0.90
38 A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Arch 2008 0.89
39 High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 2003 0.88
40 Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 2013 0.88
41 Relevance of periostin splice variants in renal cell carcinoma. Am J Pathol 2011 0.88
42 Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS One 2009 0.86
43 Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 2012 0.86
44 VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Mod Pathol 2010 0.86
45 Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer 2012 0.85
46 Expression and amplification of therapeutic target genes in retinoblastoma. Graefes Arch Clin Exp Ophthalmol 2004 0.85
47 KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst 2003 0.84
48 Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003 0.84
49 Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Anticancer Res 2004 0.83
50 Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking? Virchows Arch 2012 0.77
51 KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics Proteomics 2012 0.76
52 The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. J Pathol 2013 0.76
53 Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells. Cell Tissue Res 2014 0.75
54 Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunol Res 2013 0.75
55 Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma. Exp Mol Pathol 2013 0.75